Indeed, our findings established that treatment with cholesterol or mevalonate is able to increase the amount of perilipin-2 in all breast cancer cell lines examined, determining a further feature that could lead to greater aggressiveness and resistance to pharmacological treatments currently used in clinical practice, induced by mevalonate and cholesterol treatment. Here, PLIN2 is linked to breast cancer.